Redondo Beach, California 90277

  • Pancreatic Cancer


The purpose of this study is to determine whether the combination of MM-141 plus nab-paclitaxel and gemcitabine is more effective than nab-paclitaxel and gemcitabine alone based on Progression Free Survival (PFS) in front-line metastatic pancreatic cancer patients with high serum levels of free IGF-1.

Study summary:

This is a randomized, double-blind, placebo-controlled Phase 2 study of MM-141 plus nab-paclitaxel and gemcitabine or placebo plus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer. All patients will be initially screened for free IGF-1 status. Eligible patients with high free IGF-1 will be randomized to receive MM-141 plus nab-paclitaxel and gemcitabine or placebo plus nab-paclitaxel and gemcitabine and patients. Patients with low free IGF-1 or patients who have high free IGF-1 but are not otherwise eligible will be followed in an observational group.


Inclusion Criteria: - Metastatic adenocarcinoma of the pancreas. Patients with islet cell neoplasms are not eligible. - Patient must have received no prior radiotherapy, surgery, chemotherapy, or investigational therapy for the treatment of metastatic disease. - Blood sample sent for free IGF-1 testing - ECOG performance status (PS) of 0 or 1 Exclusion Criteria: - Patients who only present with localized disease - Patients with CNS malignancies (primary or metastatic) - Clinically significant cardiac disease



Primary Contact:

Study Director
MM-141 Medical Director, MD
Merrimack Pharmaceuticals

Backup Contact:


Location Contact:

Redondo Beach, California 90277
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.